Your browser is no longer supported. Please, upgrade your browser.
Settings
PGNX Progenics Pharmaceuticals, Inc. daily Stock Chart
PGNX [NASD]
Progenics Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own0.52% Shs Outstand85.94M Perf Week14.16%
Market Cap550.88M Forward P/E- EPS next Y-0.22 Insider Trans0.00% Shs Float83.41M Perf Month-19.17%
Income-50.30M PEG- EPS next Q-0.18 Inst Own74.40% Short Float13.42% Perf Quarter-24.50%
Sales13.70M P/S40.21 EPS this Y-605.40% Inst Trans0.88% Short Ratio6.65 Perf Half Y-14.99%
Book/sh0.85 P/B7.54 EPS next Y62.00% ROA-32.00% Target Price12.50 Perf Year-7.90%
Cash/sh1.02 P/C6.30 EPS next 5Y- ROE-75.50% 52W Range5.01 - 9.42 Perf YTD7.73%
Dividend- P/FCF- EPS past 5Y5.30% ROI-44.60% 52W High-31.19% Beta2.43
Dividend %- Quick Ratio6.30 Sales past 5Y-3.60% Gross Margin- 52W Low29.34% ATR0.41
Employees64 Current Ratio6.30 Sales Q/Q39.30% Oper. Margin- RSI (14)41.42 Volatility6.93% 5.25%
OptionableYes Debt/Eq0.76 EPS Q/Q13.50% Profit Margin- Rel Volume0.71 Prev Close6.41
ShortableYes LT Debt/Eq0.68 EarningsOct 30 BMO Payout- Avg Volume1.68M Price6.48
Recom1.50 SMA20-9.49% SMA50-16.01% SMA200-10.38% Volume281,416 Change1.09%
Sep-14-18Downgrade Needham Strong Buy → Buy $16 → $12
Aug-01-18Reiterated Needham Strong Buy $14 → $16
Feb-06-17Upgrade Needham Buy → Strong Buy $11 → $14
Oct-27-16Initiated Aegis Capital Buy
Oct-23-15Upgrade Jefferies Hold → Buy
Aug-07-15Reiterated Needham Buy $9 → $11
Aug-06-15Reiterated Brean Capital Buy $11 → $14
Feb-03-14Upgrade Needham Hold → Buy $8
Aug-30-12Initiated Stifel Nicolaus Hold
Jul-30-12Downgrade Needham Buy → Hold
Feb-10-11Upgrade Brean Murray Hold → Buy $13
Oct-14-09Downgrade Needham Buy → Hold
May-12-09Reiterated RBC Capital Mkts Outperform $14 → $12
Mar-16-09Reiterated RBC Capital Mkts Outperform $21 → $14
Mar-16-09Downgrade Oppenheimer Outperform → Perform
Mar-16-09Downgrade Brean Murray Buy → Hold
Mar-12-09Initiated FTN Equity Capital Neutral
Aug-11-08Reiterated RBC Capital Mkts Outperform $19 → $21
Jul-02-08Downgrade Friedman Billings Mkt Perform → Underperform $9 → $12
Jun-06-08Reiterated Ladenburg Thalmann Buy $17 → $40
Sep-20-18 10:43AM  Progenics Pharma's Stock Down on Dismal Phase III Study Data Zacks
Sep-17-18 06:00AM  Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma GlobeNewswire
Sep-14-18 08:00AM  Todays Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals ACCESSWIRE -6.34%
Sep-13-18 04:28PM  Qualcomm and Tailored Brands rise; Kroger stumbles Associated Press -17.88%
12:40PM  Here's Why Shares of Progenics Pharmaceuticals Inc. Sank Today Motley Fool
08:42AM  The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Foamix Pharmaceuticals ACCESSWIRE
Sep-12-18 05:21PM  After-hours buzz: PVTL, PGNX & more CNBC
04:49PM  Progenics stock falls on missed study endpoint MarketWatch
04:01PM  Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404 GlobeNewswire
Aug-27-18 07:55AM  Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-07-18 10:12PM  Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM  Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Aug-01-18 09:01AM  Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial Benzinga
Jul-31-18 07:17PM  Progenics: 2Q Earnings Snapshot Associated Press
04:30PM  Following Azedras Approval, Progenics Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update GlobeNewswire
11:40AM  FDA approves first non-surgical treatment for 2 rare cancers American City Business Journals
09:01AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:10AM  Todays Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma ACCESSWIRE
07:40AM  3 Big Stock Charts for Tuesday: Netflix, Unum Group and Dentsply Sirona InvestorPlace
Jul-30-18 09:46PM  Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma GlobeNewswire +8.49%
04:04PM  FDA approves Progenics' treatment for rare adrenal gland tumors Reuters
03:35PM  FDA approves Progenics' treatment for two rare tumors Reuters
01:46PM  The Week Ahead: Apple And Tesla Earnings, FOMC Meeting, Sonos IPO Benzinga
08:10AM  Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Gilead Sciences ACCESSWIRE
Jul-26-18 08:57AM  3 Stocks That Could Double Your Money Motley Fool
Jul-03-18 09:31AM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
Jul-02-18 03:23PM  4 Drug and Biotech Stocks Awaiting FDA Decisions in July InvestorPlace
08:23AM  4 Drug and Biotech Stocks Awaiting FDA Decisions in July Zacks
Jun-28-18 07:35AM  Complimentary Technical Snapshots on Puma Biotech and Three More Biotech Stocks ACCESSWIRE
Jun-27-18 06:01AM  3 Biotech Stocks With Major Potential Catalysts in July Motley Fool
Jun-26-18 08:30AM  Progenics Pharmaceuticals Completes Enrollment of Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL in Prostate Cancer GlobeNewswire
Jun-25-18 08:30AM  Progenics Pharmaceuticals Presents Data Validating its Artificial Intelligence Imaging Analysis Technology for Use with PSMA-Targeted SPECT/CT GlobeNewswire
Jun-21-18 08:15AM  New Research: Key Drivers of Growth for Five Below, Progenics Pharmaceuticals, Advanced Micro Devices, Agilysys, Altair Engineering, and Semtech Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jun-19-18 07:41AM  Is There An Opportunity With Progenics Pharmaceuticals Incs (NASDAQ:PGNX) 21% Undervaluation? Simply Wall St.
Jun-08-18 07:00AM  Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors GlobeNewswire
Jun-04-18 08:30AM  Progenics Pharmaceuticals Announces Presentation of Updated Data from the Pivotal Trial of AZEDRA® (iobenguane I 131) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-31-18 08:45AM  Progenics Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference GlobeNewswire
08:30AM  Progenics Artificial Intelligence Technology for Automated Analysis of PSMA Targeted Prostate Cancer Images to be Featured at the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting GlobeNewswire
May-22-18 08:30AM  Progenics Announces JAMA Oncology Publication Highlighting Companys Imaging Analysis Platform GlobeNewswire
08:01AM  Zacks.com featured highlights include: VASCO Data, Progenics, Denny's, Columbus McKinnon and Equity Commonwealth Zacks
May-21-18 10:09AM  5 Stocks in Focus on New Analyst Coverage Zacks
May-15-18 10:12AM  Edited Transcript of PGNX earnings conference call or presentation 9-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-09-18 08:34AM  Progenics: 1Q Earnings Snapshot Associated Press +5.34%
07:30AM  Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update GlobeNewswire
May-08-18 10:01AM  Zacks.com featured highlights include: Camtek, Progenics Pharmaceuticals, Denny's and Dropbox Zacks
May-07-18 09:34AM  New Analyst Coverage Puts Spotlight on These 4 Stocks Zacks
May-02-18 08:05PM  Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection GlobeNewswire
May-01-18 08:20AM  Research Report Identifies Cracker Barrel Old Country Store, Enova International, Natera, Inovalon, UMH Properties, and Progenics Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-26-18 08:30AM  Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9 GlobeNewswire
Apr-25-18 05:00PM  Progenics Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-02-18 08:30AM  Progenics Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-22-18 05:48PM  Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To Breakeven Simply Wall St.
04:15PM  Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131) GlobeNewswire
Mar-20-18 08:30AM  Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire
08:05AM  Progenics Pharmaceuticals, Upcoming PDUFA Date, Analysts Target Price, Pipeline Review ACCESSWIRE
Mar-19-18 08:30AM  Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting GlobeNewswire
Mar-16-18 10:10AM  3 Hot Junior Biotech Plays Investopedia
Mar-12-18 02:00PM  5 Stocks That Are Showing Signs of Reversing TheStreet.com
Mar-09-18 04:06AM  Edited Transcript of PGNX earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 05:49PM  Why Progenics Pharmaceuticals Jumped 15.2% on Thursday Motley Fool +15.24%
10:11AM  Progenics reports 4Q loss Associated Press
07:45AM  Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update GlobeNewswire
06:30AM  Progenics Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-18 01:23PM  Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 41.88% Discount To Its Intrinsic Value Simply Wall St. +5.83%
Mar-01-18 08:00AM  Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2017 Financial Results Call for March 8 GlobeNewswire
07:35AM  Analysis: Positioning to Benefit within Penumbra, Qualys, OraSure Technologies, Air Lease, Aduro Biotech, and Progenics Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-15-18 04:30PM  Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-05-18 08:30AM  Progenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire -5.55%
Feb-01-18 04:45PM  Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting GlobeNewswire -6.15%
Jan-05-18 07:30AM  Report: Developing Opportunities within Aduro Biotech, Progenics Pharmaceuticals, Gevo, OSI, Senseonics, and Donnelley Financial Solutions Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-04-18 02:20PM  Tim Chiang Upbeat on These Two Biotech Players Circling FDA Approvals in 2018: Synergy Pharmaceuticals Inc., Progenics Pharmaceuticals SmarterAnalyst
Jan-02-18 08:30AM  Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404 GlobeNewswire
Dec-29-17 05:22PM  Goldman Sachs and Hess slide while PepsiCo and TiVo rise Associated Press
01:21PM  Why Progenics Pharmaceuticals, Inc.'s Shareholders Came to Their Senses Motley Fool
09:50AM  Progenics Pharma Surges on FDA Decision 24/7 Wall St.
08:40AM  Progenics shares jump 21% premarket after FDA says it will review treatment for rare cancer MarketWatch
08:30AM  Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma GlobeNewswire
Dec-26-17 11:58AM  ETFs with exposure to Progenics Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-22-17 09:21AM  Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017 Capital Cube
07:18AM  Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : December 22, 2017 Capital Cube
Dec-12-17 03:20PM  Progenics Pharmaceuticals, Inc. Value Analysis (NASDAQ:PGNX) : December 12, 2017 Capital Cube
Dec-11-17 07:22AM  Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : December 11, 2017 Capital Cube -8.59%
Dec-10-17 06:30PM  Edited Transcript of PGNX earnings conference call or presentation 2-Nov-17 12:30pm GMT Thomson Reuters StreetEvents
Dec-07-17 05:43PM  Why Progenics Pharmaceuticals Incs (PGNX) Ownership Structure Is Important Simply Wall St. +7.75%
Nov-19-17 07:34PM  Estimating The Fair Value Of Progenics Pharmaceuticals Inc (PGNX) Simply Wall St.
Nov-02-17 09:11AM  Progenics reports 3Q loss Associated Press
08:00AM  Progenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Update GlobeNewswire
07:45AM  Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma GlobeNewswire
06:45AM  Progenics Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 08:30AM  Progenics Pharmaceuticals to Participate in November Investor Conferences GlobeNewswire
Oct-29-17 03:41PM  What You Must Know About Progenics Pharmaceuticals Incs (PGNX) Financial Strength Simply Wall St.
Oct-23-17 11:44AM  Progenics Pharmaceuticals, Inc. Value Analysis (NASDAQ:PGNX) : October 23, 2017 Capital Cube
08:30AM  Progenics Pharmaceuticals Sets Third Quarter 2017 Financial Results Call for November 2 GlobeNewswire
Oct-20-17 08:26AM  Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US : October 20, 2017 Capital Cube
Oct-16-17 04:30PM  Progenics Pharmaceuticals Announces Presentations on AZEDRA® (iobenguane I 131) and its Prostate Cancer Programs at the 30th Annual Congress of the European Association of Nuclear Medicine GlobeNewswire
Oct-12-17 08:36PM  Have Investors Already Priced In Progenics Pharmaceuticals Incs (PGNX) Growth? Simply Wall St.
Oct-05-17 11:15AM  ETFs with exposure to Progenics Pharmaceuticals, Inc. : October 5, 2017 Capital Cube
Oct-04-17 08:30AM  Data from Pivotal Phase 2b Study of Progenics AZEDRA® (iobenguane I 131) to be Presented at the North American Neuroendocrine Tumor Society 2017 Annual Symposium GlobeNewswire
Sep-27-17 08:07AM  3 Top Stocks in Healthcare Motley Fool
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.